Surfactant (drug to open collapsed lungs) with budesonide (drug to reduce inflammation) in reducing duration of use of ventilator and improving outcome in very small preterm babies : Open labelled randomized controlled trial
Not Applicable
- Conditions
- Health Condition 1: P22- Respiratory distress of newborn
- Registration Number
- CTRI/2020/07/026502
- Lead Sponsor
- Munmun Sahney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Receiving mechanical ventilation via an endotracheal tube, or infants receiving non-invasive respiratory support including continuous positive airway pressure (CPAP), non-invasive intermittent positive pressure ventilation (NIPPV) or nasal high flow (HF), and a clinical decision to treat the infant with exogenous surfactant.
Exclusion Criteria
1. Infant is considered non-viable (less than 23 weeks) or is not going to be admitted to the neonatal intensive care unit (NICU)
2. Known or suspected major congenital anomaly that are likely to affect respiratory status (upper airway obstruction, severe pulmonary hypoplasia following oligohydramnios, congenital lung malformation, and major congenital heart disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method